Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly Thanks, everybody, for joining us here at the conference. Happy to have Kevin Conroy and Aaron Bloomer from Exact Sciences with us here today.
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)
Editor's note: The headline of this story was updated to correct an error related to the reported day of the week.
Why Is Exact Sciences Stock Trading Higher On Monday?
On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson Thank you both. Kevin, while you're walking up to the podium there, maybe you can talk a little bit about your recent purchase.
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
Exact Sciences presents new positive evidence backing the development of an MCED test.
Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues for a year or more. Despite its long history of losses, the company has comfortable liquidity cushions and will not need to raise cash to continue its normal operations.
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook.
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
On Tuesday, Exact Sciences Corp. EXAS reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20.
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.
Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Erik Holznecht - Director, Investor Relations Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Tycho Peterson - Jefferies Andrew Brackman - William Blair Doug Schenkel - Wolfe Research Dan Brennan - Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Dan Arias - Stifel Jack Meehan - Nephron Research Patrick Donnelly - Citi Dan Leonard - UBS Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Andrew Cooper - Raymond James Mark Massaro - BTIG Operator Hello. At this time, I would like to welcome everyone to the Exact Sciences Third Quarter 2024 Earnings Conference Call.
Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook
Exact Sciences stock fell sharply Tuesday after the company cut its full-year outlook and posted weaker-than-expected results. The post Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook appeared first on Investor's Business Daily.
Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to break-even earnings per share a year ago.
